Certara, Inc. ( (CERT) ) has released its Q3 earnings. Here is a breakdown of the information Certara, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Certara, Inc. is a global leader in model-informed drug development, offering biosimulation software and services to biopharmaceutical companies, academic institutions, and regulatory agencies worldwide. In its third quarter of 2025, Certara reported a revenue increase to $104.6 million, marking a 10% growth compared to the same period in 2024. The company also saw a significant rise in software revenue by 22% and a modest increase in services revenue by 3%. Notably, Certara transitioned from a net loss to a net income of $1.5 million, reflecting a 211% improvement year-over-year. The company’s adjusted EBITDA also rose by 7% to $35.2 million. Certara’s strategic focus on biosimulation technology is evident with the launch of new software products like CertaraIQ for QSP modeling, aimed at expanding its market reach. Despite some hesitancy in spending within certain service areas, the company remains optimistic, adjusting its profitability targets upwards and narrowing its revenue guidance for the full year 2025. Looking ahead, Certara is poised for sustainable growth, driven by continued investment in research and development and commercial efforts, as it aims to achieve its updated financial guidance for the year.